Considerations on the Demography of BIA-ALCL in European Countries Based on an E(A)SAPS Survey

BACKGROUND

A growing body of evidence indicates that breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is associated with the use of certain breast implants. Regional variations have been reported, and a genetic susceptibility has also been suggested. However, large variations in the ability to correctly diagnose BIA-ALCL and to further report and register cases exist between countries and may in part explain variations in the demography.

MATERIAL AND METHODS

A survey was conducted by The European Association of Societies of Aesthetic Plastic Surgery E(A)SAPS and sent to 48 European countries. The primary aim was to identify the total number of confirmed cases of and deaths from BIA-ALCL in each country during four consecutive measurements over a two-year period.

RESULTS

An increase in BIA-ALCL cases during four repeated measurements from a total of 305 in April 2019 to 434 in November 2020 was reported by 23 of the 33 responding countries. A nearly 100-fold variation in the number of cases per million inhabitants was noted, where Netherlands had the highest rate (4.12) followed by Finland (1.99). Countries with the lowest reported rates were Austria (0.078), Romania (0.052) and Turkey (0.048).

CONCLUSION

The current study displays a notable variation ßin the number of confirmed BIA-ALCL cases across Europe, even for countries with established breast implant registers. Variations in diagnosis and reporting systems may explain the differences, but the influence of genetic variations and the prevalence of high-risk implants cannot be excluded. Incomplete sales data along with medical tourism preclude an absolute risk assessment.

LEVEL OF EVIDENCE IV

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

EASAPS/ESPRAS Considerations in getting back to work in Plastic Surgery with the COVID-19 Pandemic – A European point of view

The aim of this paper is to summarize the results of a consensus process and a European webinar of the two societies, European Association of Societies of Aesthetic Surgery (EASAPS) and the European Society of Plastic, Reconstructive and Aesthetic Societies (ESPRAS) on what is considered safe practice based on the scientific knowledge we have today. This review of the current situations gives considerations which have to be taken into account when getting back to work in plastic surgery with COVID-19 in Europe. At all times, one should be familiar the local and regional infection rates in the community, with particular emphasis on the emergence of second and third waves of the pandemic. Due to the fast-evolving nature of the COVID-19 pandemic the recommendations aim to be rather considerations than fixed guidelines and might need to be revised in near future.

Swiss guidelines for the treatment and follow-up of cutaneous melanoma

Melanoma is the most common lethal cutaneous neoplasm. There is major controversy over the best management of this malignancy. In order to harmonize treatment and follow-up of melanoma patients, guidelines for the management of melanoma in Switzerland have been inaugurated. They have been approved by all Swiss medical societies involved in the care of melanoma patients.

[Surgical treatment of malignant melanoma]

Early diagnosis and total tumor excision are fundamental to assure a favorable outcome in the treatment of the malignant melanoma. Previously a large local excision up to 5 cm was recommended. In the past two decades some prospective studies showed the same survival rate when using narrower margins of excision (1-3 cm). The elective lymphadenectomy increases the survival rate only in a small group of patients and has a high rate of complications. The concept of lymphatic mapping can greatly help in finding the lymph node ("sentinel lymph node") which is the first one to receive lymphatic drainage from the affected area. This node has the highest probability of containing a metastasis and is excised. With this procedure the number of patients requiring lymphadenectomy can be limited to those who have documented lymph node metastases. The sentinel biopsy technique can provide new insight into the tumor biology of melanoma and helps in determining adjuvant therapy. In order to evaluate the influence of sentinel node biopsy on survival rate of melanoma patients clinical trials have been designed. Systemic melanoma metastases carry a poor prognosis. Surgical resection of isolated metastases may provide good palliation, in combination with other therapies.